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OBJECTIVE — To investigate whether screening-detected diabetic patients differ from dia-
betic patients newly diagnosed in general practice with regard to the presence of microvascular
complications.
RESEARCH AND DESIGN METHODS — Diabetic patients, identified by a popula-
tion-based targeted screening procedure consisting of a screening questionnaire and a fasting
capillary whole–blood glucose measurement followed by diagnostic testing, were compared
with patients newly diagnosed with diabetes in general practice. Retinopathy was assessed with
fundus photography, impaired foot sensitivity was assessed with Semmes-Weinstein monofila-
ments, and the presence of microalbuminuria was measured by means of the albumin-to-
creatinine ratio (ACR).
RESULTS — A total of 195 screening-detected type 2 diabetic patients and 60 patients newly
diagnosed in general practice participated in the medical examination. The prevalence of reti-
nopathy was higher in screening-detected type 2 diabetic patients than in patients newly diag-
nosed in general practice, but not significantly higher. The prevalence of retinopathy was 7.6%
(95% CI 4.6–12.4) in screening-detected type 2 diabetic patients and 1.9% (0.3–9.8) in patients
newly diagnosed in general practice. The prevalence of impaired foot sensitivity was similar in
both groups, 48.1% (40.9–55.3) and 48.3% (36.2–60.7), respectively. The ACR was 0.61
(interquartile range 0.41–1.50) in screening-detected type 2 diabetic patients and 0.99 (0.53–
2.49) in patients newly diagnosed in general practice. The difference in prevalence of microalbu-
minuria was not statistically significant. The prevalence of microalbuminuria was 17.2% (95%
CI 12.5–23.2) and 26.7% (17.1–39.0) in screening-detected type 2 diabetic patients and patients
newly diagnosed in general practice, respectively.
CONCLUSIONS — Targeted screening
for type 2 diabetes (with a screening question-
naire as a first step) resulted in the identifica-
tion of previously undiagnosed diabetic
patients with a considerable prevalence of mi-
crovascular complications.
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T ype 2 diabetes is a common andserious disease with chronic compli-cations, and it constitutes a substan-
tial burden for both the patient and the
health care system. Type 2 diabetes is
characterized by an asymptomatic phase
between the actual onset of diabetic hy-
perglycemia and clinical diagnosis. This
phase has been estimated to last at least
4–7 years, and consequently 30–50% of
type 2 diabetic patients remain undiag-
nosed (1). Untreated hyperglycemia is an
explanation for the relatively high preva-
lence of retinopathy in newly diagnosed
diabetic patients (1,2). Patients in clinical
practice are predominantly diagnosed be-
cause they have symptoms of hyperglyce-
mia, but screening for type 2 diabetes
might make it possible to identify diabetic
patients much earlier in the asymptomatic
phase. The assumption that early detec-
tion and early treatment may prevent or
delay the progression of diabetes and its
complications has given rise to the recom-
mendations to screen for type 2 diabetes
(3,4).
Screening for type 2 diabetes can be
carried out in various ways. Targeted
screening might be a practical and effi-
cient way of screening because diagnostic
testing is then restricted to individuals
who are at high risk of having undiag-
nosed type 2 diabetes. To date, targeted
screening studies have focused on the
yield of the screening procedure (5,6). To
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our knowledge, no previous studies have
reported the prevalence of microvascular
complications in diabetic patients identi-
fied by targeted screening. It is unclear to
what extent these patients differ from
newly diagnosed diabetic patients in gen-
eral practice. With screening one would
expect to identify patients earlier in the
development of hyperglycemia and with a
lower prevalence of complications. In
view of these considerations, we com-
pared the prevalence of retinopathy,
impaired foot sensitivity, and microalbu-
minuria at the time of diagnosis in screen-
ing-detected patients with the prevalence
observed in diabetic patients who were
newly diagnosed in general practice. This
issue was addressed in a population-
based targeted screening program that
was based on a screening questionnaire
and a fasting capillary whole–blood glu-
cose measurement to select a high-risk
population for diagnostic testing (7).
RESEARCH DESIGN AND
METHODS
Study population
Diabetic patients detected by screen-
ing. The population-based targeted
screening procedure was carried out from
1998 to 2000 among the 11,679 inhabit-
ants, aged 50–75 years, of the West Fries-
land region of the Netherlands, as was
previously described in detail (7). In brief,
the first step of the screening procedure
consisted of the symptom risk question-
naire (SRQ), which was developed in the
Hoorn Study to identify people at high
risk of having undiagnosed type 2 diabe-
tes (8). The SRQ was validated against the
1999 World Health Organization (WHO)
diagnostic criteria of diabetes in a separate
random sample of the population of
Hoorn. The sensitivity, specificity, and
positive and negative predictive values of
a SRQ score of 6 are 66, 70, 13, and 97%,
respectively (A.M.W.S., unpublished
data). The SRQ includes questions about
age, sex, BMI, family history of diabe-
tes, use of antihypertensive medication,
frequent thirst, shortness of breath, clau-
dication, and use of a bicycle for transpor-
tation. It was sent by mail to every person
in the targeted screening population. Par-
ticipants with an SRQ score6 were con-
sidered to be at low risk for undiagnosed
diabetes and were therefore not invited to
participate in any further testing. For in-
dividuals with a SRQ score 6, the sec-
ond step of the screening was a fasting
capillary whole–blood glucose measure-
ment. In all individuals with a fasting cap-
illary whole– blood glucose level 5.5
mmol/l, a venous sample was drawn on
the same occasion and a 75-g oral glucose
tolerance test (OGTT) was performed
within 2 weeks. Individuals with a fasting
capillary whole– blood glucose 8.5
mmol/l had two fasting plasma glucose
(FPG) measurements within 2 weeks. The
1999 WHO diagnostic criteria for diabe-
tes were applied, i.e. FPG7.0 mmol/l on
two separate occasions or a plasma glu-
cose level11.1 mmol/l 2 h after the glu-
cose load of the OGTT (9). The total
response for the invitation to the screen-
ing was 78% and the SRQ calculated for
7,736 participants, after the exclusion of
741 nonparticipants, 417 previously di-
agnosed diabetic patients, and 275 people
missing data or informed consent. A total
of 3,301 participants had a SRQ score6.
The response rates for the capillary blood
glucose measurement and OGTT were
87 and 89%, respectively. The nonpartic-
ipants of the SRQ were significantly
younger than participants and more likely
to be men. The nonresponders for the
OGTT were older than people who did
participate. In total, 217 previously undi-
agnosed diabetic patients were identified
in the targeted screening (7).
Diabetic patients newly diagnosed in
general practice
All diabetic patients, aged 50–75 years,
who were newly diagnosed from 1999 to
2001 in general practice in the towns of
Den Helder and Medemblik (situated to
the north of the West Friesland region)
were invited to participate in the study.
For people without symptoms of hyper-
glycemia, a fasting capillary whole–blood
glucose measurement 6.1 mmol/l or
FPG 7.0 mmol/l on two separate occa-
sions were the criteria for diagnosis of di-
abetes. For individuals with symptoms of
hyperglycemia, one fasting capillary
whole–blood glucose measurement6.1
mmol/l or one FPG7.0 mmol/l was suf-
ficient for a diagnosis of diabetes, accord-
ing to the guidelines of the Dutch College
of General Practice (10). These diagnostic
cutoff points are in accordance with the
1999 WHO diagnostic criteria for FPG.
The general practitioners identified a total
of 81 newly diagnosed diabetic patients.
Of these, 10 were too young to participate
in the present study (50 years of age).
As a result, 71 newly diagnosed diabetic
patients were eligible and therefore consec-
utively invited to participate in the study.
Ascertainment of referral of all newly di-
agnosed diabetic patients was not possi-
ble because of Dutch privacy legislation.
Individuals with screening-detected
type 2 diabetes (SDM) and all diabetic
patients who were newly diagnosed in
general practice (GPDM) were invited to
undergo an extensive medical exami-
nation, including assessment of micro-
vascular complications. The screening
procedure, diagnostic tests, and physical
examination were carried out in a stan-
dardized manner by trained PhD students
and research assistants at the Diabetes Re-
search Center in Hoorn. All participants
gave written informed consent. The ethics
committee at Vrije University Medical
Center approved the study.
Measurements
Capillary fasting whole– blood glucose
levels were obtained with a Hemocue
Blood Glucose Analyzer based on the glu-
cose-dehydrogenase method (Hemocue
Nederland, Oisterwijk, the Netherlands).
Plasma glucose concentrations were as-
sessed by means of a glucose hexokinase
method (Roche Diagnostics, Mannheim,
Germany). HbA1c was determined by ion-
exchange high-performance liquid chro-
matography with a modular diabetes
monitoring system (Bio-Rad, Veenendaal,
the Netherlands). Serum total cholesterol,
HDL cholesterol, and triglycerides were
measured by means of enzymatic tech-
niques (Boehringer-Mannheim, Mann-
heim, Germany). The Friedewald formula
was used to calculate LDL cholesterol, ex-
cept when the triglyceride level was4.5
mmol/l. Information about smoking hab-
its, medication use, and educational level
was assessed by means of a questionnaire.
Weight, height, and hip and waist cir-
cumferences were measured with sub-
jects barefoot and wearing only light
clothes. Overweight was defined as BMI
25 kg/m2 (11). Blood pressure was cal-
culated as the mean of two measurements
performed in a sitting position after 5 min
of rest, using a random-zero sphygmoma-
nometer (Hawksley-Gelman, Lancing,
Sussex, U.K.). Individuals were consid-
ered hypertensive if they had a diastolic
blood pressure 90 mmHg, had a sys-
tolic blood pressure140 mmHg, and/or
were taking antihypertensive medication
(12).
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Microvascular complications
To assess the presence of diabetic retinop-
athy, fundus photography was carried out
following mydriasis of both eyes with
tropicamide and phenylephrine eye
drops. One photograph was centred on
the macula and the other nasally on the
optic disc. A 45o CR5 nonmydriatic reti-
nal camera (Canon, Tokyo, Japan) was
used, interfaced to a 3CCD Color Video
Camera (Sony, Tokyo, Japan). Retinopa-
thy was graded according to the Wiscon-
sin grading system (13) and defined as a
Wisconsin grade 1.5. The ophthalmol-
ogist who carried out the grading of the
photographs was blinded to the method
of detection of the diabetic patients.
Foot sensitivity was assessed with
Semmes-Weinstein monofilaments. The
5.07 (10-g) monofilament was applied to
nine sites on each foot. Each site was
tested three times in random order, and
two or more failures per site to feel the
monofilament was regarded as an incor-
rect answer. Impaired foot sensitivity was
considered to be present if one or more
incorrect answers were given for either
foot (14,15).
The albumin-to-creatinine ratio (ACR)
was calculated to determine the presence
of microalbuminuria. Urinary albumin
was measured by rate nephelometry (Ar-
ray Protein System; Beckman, Galway,
Ireland). Urinary creatinine was mea-
sured by means of a modified Jaffe´
method. Subjects were classified as hav-
ing (micro)albuminuria if they had an
ACR 2.0 mg/mmol (16). In 26 patients
in the SDM group and in 5 in the GPDM
group, the albumin concentrations were
below the detection threshold. These pa-
tients were considered not to have mi-
croalbuminuria. The prevalence of
microalbuminuria was also determined
after exclusion of 28 SDM and 10 GPDM
who used an ACE inhibitor or an angio-
tensin II receptor blocker.
Statistical analyses
The characteristics of SDM and GPDM
were compared using Student’s t test for
continuous variables, the 2 test for di-
chotomous variables, and the Mann-
Whitney U test for skewed variables.
Fasting plasma glucose, HbA1c, and tri-
glycerides were presented as median and
interquartile range because of their
skewed distribution. CIs were calculated
with the Confidence Interval Analysis
software, version 2.0 (17). A P value
0.05 was considered statistically signif-
icant, based on two-sided tests. SPSS for
Windows version 10.1 was used for all
analyses.
RESULTS — In total, 195 of the 217
SDM participated in the assessment of mi-
crovascular complications. The general
practitioners identified a total of 71 newly
diagnosed diabetic patients. Of these,
eight declined participation in the study
and three did not participate in the assess-
ment of microvascular complications. As
a result, a total of 195 SDM and 60 GPDM
underwent extensive physical examina-
tion. Nonparticipants in the examination
tended to be older in both groups, but this
difference was not statistically significant.
There were no significant differences be-
tween participants and nonparticipants in
the physical examination in either group
with respect to sex and glucose levels
(data not shown). In the SDM, data were
complete for 184, 181, and 192 patients
for retinopathy, foot sensitivity, and mi-
croalbuminuria, respectively. In the
GPDM, data on foot sensitivity and mi-
croalbuminuria were complete for all pa-
tients, but data on retinopathy were only
complete for 54 patients. The absence of
photographs, poor quality of photo-
graphs, and prevalent eye disease that
precluded fundus photography explained
the missing data on retinopathy in both
groups. Monofilament data were missing
for SDM because foot sensitivity was mea-
sured during the fifth or sixth visit to the
research center; 14 patients did not attend
this visit. There were no significant differ-
ences between patients with and without
missing data on individual microvascular
complications (data not shown). No dif-
ference was observed in educational level
between SDM and GPDM.
Table 1 shows the baseline character-
istics of diabetic patients identified by
screening and newly diagnosed in gen-
eral practice. The SDM were slightly, but
not significantly, older than GPDM. The
GPDM were characterized by significantly
higher FPG and HbA1c levels than SDM.
HDL cholesterol in the GPDM was lower
than in the SDM, and GPDM were signif-
icantly less likely to be overweight or have
hypertension and more likely to smoke.
Table 2 shows the prevalence of mi-
crovascular complications at the time of
diagnosis in diabetic patients identified
by screening and in general practice. SDM
were more likely to have retinopathy, but
this difference was not statistically signif-
icant. Background retinopathy (Wiscon-
sin grade 1.5) was present in 11 SDM.
There were three cases of mild nonprolif-
erative retinopathy (Wisconsin grade 2.0
and 3.0) in the SDM group and one pa-
tient with (pre)proliferative retinopathy
(Wisconsin grade 4.0) in the GPDM
group. The prevalence of impaired foot
sensitivity was similar in SDM and
GPDM. In both groups, two patients were
unable to feel the 10-g monofilament. Al-
though the ACR was significantly higher
in GPDM, the prevalence of microalbu-
minuria was not statistically significantly
higher in this group. Macroalbuminuria
(ACR30 mg/mmol) was present in one
of the SDM and in three of the GPDM.
CONCLUSIONS — The prevalence
of microvascular complications was simi-
lar in diabetic patients who were detected
by a targeted screening procedure and in
newly diagnosed diabetic patients in gen-
eral practice. This similarity was observed
despite the marked difference in glycemic
parameters between the two groups.
This is the first study to compare dia-
betic microvascular complications at the
time of diagnosis in patients detected by
targeted screening and patients newly di-
agnosed in general practice. With screen-
ing one would expect to identify patients
soon after the actual onset of the disease,
i.e., earlier in the development of hyper-
glycemia. One would also expect to iden-
tify diabetic patients with a lower
prevalence of microvascular complica-
tions. However, our findings were not
entirely in accordance with these expec-
tations. The glucose and HbA1c levels
were indeed lower in SDM compared
with GPDM, which might be an indica-
tion that SDM were identified earlier in
the development of hyperglycemia. In
contrast, the prevalence of microvascular
complications did not follow a similar
pattern. As microvascular complications
have been shown to be affected not only
by glucose but also by hypertension and
other components of the metabolic syn-
drome (18,19), the targeted screening ap-
proach might explain the similarity in
prevalence of microvascular complica-
tions. The screening questionnaire in-
cludes questions on age, sex, BMI, family
history of diabetes, use of antihyperten-
sive medication, frequent thirst, shortness
of breath, claudication, and use of a bicy-
cle for transportation. Therefore, the tar-
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geted screening procedure identifies
diabetic patients with a high prevalence of
hypertension, obesity, and lipid abnor-
malities (7), which in turn might partly
explain the relatively high prevalence of
microvascular complications in this
group.
The difference in diagnostic strategy
between the SDM and the GPDM did not
influence the microvascular findings. In
the screening-detected type 2 diabetic
group, the diagnosis of diabetes was
based on two elevated FPG values or one
elevated 2-h value of the OGTT. In con-
trast, GPDM were diagnosed on the basis
of elevated FPG values only. However, the
diagnostic FPG value and the 2-h plasma
glucose values have been shown to be
equivalent in the diagnosis of diabetes
and the association with microvascular
complications (9,20,21). Consequently,
it seems unlikely that the difference in
diagnosis would explain any (lack of)
differences in microvascular complica-
tions between SDM and GPDM. Misclas-
sification of microvascular complications
is another unlikely explanation for our
findings because retinopathy, impaired
foot sensitivity, and microalbuminuria
were assessed and graded according to
methods that are widely used and have been
internationally validated (13,14,16).
The relatively small sample size of the
SDM and GPDM groups and the small
number of patients with complications
are limitations of this cross-sectional
study. The similarity in the prevalence of
complications between SDM and GPDM
might be partly due to chance due to the
limited power. If the number of GPDM
had been higher, the difference in micro-
albuminuria might have become statisti-
cally significant. However, the inconsistent
differences in prevalence in retinopathy
and foot insensitivity between the two
groups are not likely to be affected by a
higher number of GPDM.
It seems unlikely that nonresponse
bias has influenced the estimated prev-
alence of microvascular complications
because the age difference between par-
ticipants and nonparticipants in the phys-
ical examination was not significant and
was present in both groups. SDM and
GPDM patients did not differ in educa-
tional level, and it therefore seems un-
likely that a concomitant difference in
degree of disease awareness has affected
our results. Coverage of care has not in-
fluenced the study results because every-
one is insured for health care in the
Netherlands. As we were unable to ascer-
tain that all newly diagnosed diabetic pa-
tients were referred for our study (due to
privacy legislation), we cannot exclude
that newly diagnosed diabetic patients
with more or more severe microvascular
complications did not participate in the
study.
People with a relatively mild form of a
disease, with a slower progression, are
more likely to be identified by screening.
People with a more progressive type of
disease will probably present with symp-
toms and may be diagnosed in general
practice, independent of screening (3,
22). If a lower prevalence of complica-
tions is observed in SDM, this could be
due to detection early in the development
of hyperglycemia, a less progressive form
of hyperglycemia, or both phenomena
(length time bias). In the present study,
the observed higher prevalence of reti-
nopathy and a similar prevalence of im-
paired foot sensitivity in SDM does not
seem to support the presence of length
time bias.
Table 1—Characteristics of diabetic patients identified by screening and in general practice
SDM GPDM
n 195 60
Age (years) 63.4  7.0 61.4  7.0
Sex (M/F) (% male) 101/94 (51.8) 30/30 (50)
Symptoms at diagnosis (%) — 76.0
FPG (mmol/l) 7.9 (7.3–9.0) 9.0 (7.7–10.4)*
HbA1c (%) 6.3 (5.8–7.1) 8.3 (7.4–11.0)*
Cholesterol (mmol/l) 5.7 (1.1) 5.5 (1.0)
HDL cholesterol (mmol/l) 1.3 (0.4) 1.1 (0.3)*
LDL cholesterol (mmol/l) 3.57 (0.96) 3.50 (0.96)
Triglycerides (mmol/l) 1.7 (1.2–2.4) 1.8 (1.4–2.3)
Lipid-lowering medication (%) 20.0 16.7
BMI (kg/m2) 29.8  5.3 29.4  5.8
Overweight (%) 88.7 74.6*
Waist-to-hip ratio
Men 1.01  0.06 1.00  0.07
Women 0.92  0.08 0.92  0.07
Current smoker (%) 15.4 31.7*
Systolic blood pressure (mmHg) 141  18 141  22
Diastolic blood pressure (mmHg) 86  10 84  12
Antihypertensive medication (%) 45.1 36.7
Hypertension (%) 75.4 58.3*
Data are mean  SD or median (interquartile range). Overweight was defined as BMI 25 kg/m2, hyper-
tension as diastolic blood pressure90 mm Hg and/or systolic blood pressure140mm Hg and/or use of
antihypertensive medication. *Significantly different from SDM.
Table 2—Prevalence of microvascular complications at the time of diagnosis in diabetic pa-
tients identified by screening and in general practice
SDM GPDM
Diabetic retinopathy (%) 7.6 (4.6–12.4) 1.9 (0.3–9.8)
Impaired foot sensitivity (%) 48.1 (40.9–55.3) 48.3 (36.2–60.7)
ACR* 0.61 (0.41–1.50) 0.99 (0.53–2.49)†
Microalbuminuria (%)* 17.2 (12.5–23.2) 26.7 (17.1–39.0)
Microalbuminuria (%)‡ 14.5 (10.0–20.7) 26.0 (15.9–39.6)
Data are % (95% CI) or median (interquartile range). Retinopathy was defined as Wisconsin grade 1.5,
impaired foot sensitivity was defined as 1 incorrect answers to the monofilament for either foot, and
microalbuminuria was defined as a ACR 2.0 mg/mmol. *ACR and microalbuminuria, subjects with
missing samples excluded; †significantly different from SDM; ‡microalbuminuria, subjects with missing
samples and subjects on ACE inhibitors excluded.
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This study reports a one-time screen-
ing effort. Therefore, results may not be
generalizable to diabetic patients detected
in a population with screening at regular
intervals. Differences between these pa-
tients would depend on the duration of
the screening interval, the progression of
glucose intolerance, and the progression
of complications in the general popula-
tion. Since the SRQ selects patients with
an adverse cardiovascular risk profile and
because microvascular complications
may also develop as a result of cardiovas-
cular risk factors (i.e., hypertension), it is
possible that even with regular screening
patients identified by this targeted screen-
ing procedure would present with micro-
vascular complications.
The ultimate goal of screening is to
reduce morbidity and mortality of type 2
diabetes. Our study shows that the use of
risk factors for type 2 diabetes and cardio-
vascular risk factors in a screening test for
undiagnosed type 2 diabetes might be an
efficient way to select a group of undiag-
nosed diabetic patients who would signif-
icantly benefit. If the results of this study
were replicated, preventive diabetes care
might be redirected toward early identifi-
cation based on cardiovascular risk fac-
tors and risk factors for type 2 diabetes
rather than focusing only on glucose
screening.
In conclusion, targeted screening for
type 2 diabetes resulted in the identifica-
tion of previously undiagnosed diabetic
patients with a considerable prevalence of
microvascular complications.
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